Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance

Objectives To investigate the biologic relevance of cross-platform concordant changes in gene expression in intact human failing/hypertrophied ventricular myocardium undergoing reverse remodeling. Background Information is lacking on genes and networks involved in remodeled human LVs, and in the associated investigative best practices. Methods We measured mRNA expression in ventricular septal endomyocardial biopsies from 47 idiopathic dilated cardiomyopathy patients, at baseline and after 3–12 months of β-blocker treatment to effect left ventricular (LV) reverse remodeling as measured by ejection fraction (LVEF). Cross-platform gene expression change concordance was investigated in reverse remodeling Responders (R) and Nonresponders (NR) using 3 platforms (RT-qPCR, microarray, and RNA-Seq) and two cohorts (All 47 subjects (A-S) and a 12 patient “Super-Responder” (S-R) subset of A-S). Results For 50 prespecified candidate genes, in A-S mRNA expression 2 platform concordance (CcpT), but not single platform change, was directly related to reverse remodeling, indicating CcpT has biologic significance. Candidate genes yielded a CcpT (PCR/microarray) of 62% for Responder vs. Nonresponder (R/NR) change from baseline analysis in A-S, and ranged from 38% to 100% in S-R for PCR/microarray/RNA-Seq 2 platform comparisons. Global gene CcpT measured by microarray/RNA-Seq was less than for candidate genes, in S-R R/NR 17.5% vs. 38% (P = 0.036). For S-R global gene expression changes, both cross-cohort concordance (CccT) and CcpT yielded markedly greater values for an R/NR vs. an R-only analysis (by 22 fold for CccT and 7 fold for CcpT). Pathway analysis of concordant global changes for R/NR in S-R revealed signals for downregulation of multiple phosphoinositide canonical pathways, plus expected evidence of a β1-adrenergic receptor gene network including enhanced Ca2+ signaling. Conclusions Two-platform concordant change in candidate gene expression is associated with LV biologic effects, and global expression concordant changes are best identified in an R/NR design that can yield novel information.

[1]  Terence P. Speed,et al.  Evaluation of cross-platform and interlaboratory concordance via consensus modelling of genomic measurements , 2018, Bioinform..

[2]  L. Mestroni,et al.  Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure , 2018, BMC Genomics.

[3]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[4]  Kenneth L. Jones,et al.  Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). , 2018, The American journal of cardiology.

[5]  R. Quaife,et al.  Structural and Functional Phenotyping of the Failing Heart: Is the Left Ventricular Ejection Fraction Obsolete? , 2017, JACC. Heart failure.

[6]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[7]  E. Hirsch,et al.  PI3K and Calcium Signaling in Cardiovascular Disease , 2017, Circulation research.

[8]  Marcel E Dinger,et al.  Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data , 2017, Scientific Reports.

[9]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.

[10]  Roger D. Cox,et al.  Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy , 2017, JCI insight.

[11]  J. Port,et al.  Myocardial microRNAs associated with reverse remodeling in human heart failure. , 2017, JCI insight.

[12]  Francesco Vallania,et al.  Methods to increase reproducibility in differential gene expression via meta-analysis , 2016, Nucleic acids research.

[13]  S. Datta,et al.  Inter-platform concordance of gene expression data for the prediction of chemical mode of action , 2016, Biology Direct.

[14]  Hong Yan,et al.  Differential network analysis from cross-platform gene expression data , 2016, Scientific Reports.

[15]  Ruoxiang Jiang,et al.  A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. , 2015, JAMA internal medicine.

[16]  Lawrence Hunter,et al.  Visual analysis of biological data-knowledge networks , 2015, BMC Bioinformatics.

[17]  David P Kao,et al.  Therapeutic Molecular Phenotype of &bgr;-Blocker–Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy , 2015, Circulation. Cardiovascular genetics.

[18]  David P. Kreil,et al.  The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance , 2014, Nature Biotechnology.

[19]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[20]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[21]  Jeffrey T. Chang,et al.  Cross-Platform Prediction of Gene Expression Signatures , 2013, PloS one.

[22]  E. Heath,et al.  Current Challenges in Development of Differentially Expressed and Prognostic Prostate Cancer Biomarkers , 2012, Prostate cancer.

[23]  J. Port,et al.  Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the β1-adrenergic receptor. , 2011, Physiological genomics.

[24]  M. Bristow.  Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. , 2011, Circulation research.

[25]  D. Tilley.  G Protein–Dependent and G Protein–Independent Signaling Pathways and Their Impact on Cardiac Function , 2011, Circulation research.

[26]  M. Febbraio,et al.  PI3K(p110&agr;) Protects Against Myocardial Infarction-Induced Heart Failure: Identification of PI3K-Regulated miRNA and mRNA , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[28]  Jing Zhu,et al.  Apparently low reproducibility of true differential expression discoveries in microarray studies , 2008, Bioinform..

[29]  Lei Guo,et al.  Cross-platform comparison of SYBR® Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study , 2008, BMC Genomics.

[30]  J. Lowe,et al.  Selective Activation of Human Atrial Gα12 and Gα13 by Gαq-coupled Angiotensin and Endothelin Receptors , 2007 .

[31]  Yunyu Zhang,et al.  Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.

[32]  A. Saeed,et al.  Microarrays: an overview. , 2007, Methods in molecular biology.

[33]  D. Bers,et al.  Calcium and cardiomyopathies. , 2007, Sub-cellular biochemistry.

[34]  J. Lowe,et al.  Selective activation of human atrial Galpha12 and Galpha13 by Galphaq-coupled angiotensin and endothelin receptors. , 2007, Journal of cardiovascular pharmacology.

[35]  M. Lohse,et al.  Interstitial remodeling in β1-adrenergic receptor transgenic mice , 2006, Basic Research in Cardiology.

[36]  M. Bristow,et al.  Serial gene expression profiling in the intact human heart. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  W. Xiao,et al.  Cross-platform expression profiling demonstrates that SV40 small tumor antigen activates Notch, Hedgehog, and Wnt signaling in human cells , 2006, BMC Cancer.

[38]  Tao Han,et al.  Cross-platform comparability of microarray technology: Intra-platform consistency and appropriate data analysis procedures are essential , 2005, BMC Bioinformatics.

[39]  Yudi Pawitan,et al.  False discovery rate, sensitivity and sample size for microarray studies , 2005, Bioinform..

[40]  N. Dhanasekaran,et al.  Mitogenic signaling by lysophosphatidic acid (LPA) involves Gα12 , 2005, Oncogene.

[41]  H. Rockman,et al.  Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. , 2005, Journal of the American College of Cardiology.

[42]  S. Kong,et al.  Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. , 2005, Physiological genomics.

[43]  K. Margulies,et al.  Mixed Messages: Transcription Patterns in Failing and Recovering Human Myocardium , 2005, Circulation research.

[44]  M. Nishida,et al.  Gα12/13- and Reactive Oxygen Species-dependent Activation of c-Jun NH2-terminal Kinase and p38 Mitogen-activated Protein Kinase by Angiotensin Receptor Stimulation in Rat Neonatal Cardiomyocytes* , 2005, Journal of Biological Chemistry.

[45]  E. Lakatta,et al.  Phosphatidylinositol 3-Kinase Offsets cAMP-Mediated Positive Inotropic Effect via Inhibiting Ca2+ Influx in Cardiomyocytes , 2004, Circulation research.

[46]  N. Dhalla,et al.  Phospholipase C gene expression, protein content, and activities in cardiac hypertrophy and heart failure due to volume overload. , 2004, American journal of physiology. Heart and circulatory physiology.

[47]  P. Doevendans,et al.  MEK1-ERK2 Signaling Pathway Protects Myocardium From Ischemic Injury In Vivo , 2004, Circulation.

[48]  The eMERGE Clinical Annotation Working Group,et al.  Expression profiling — best practices for data generation and interpretation in clinical trials , 2004 .

[49]  E. Lakatta,et al.  Phosphatidylinositol 3-Kinase Offsets cAMP-Mediated Positive Inotropic Effect via Inhibiting Ca 2 Influx in Cardiomyocytes , 2004 .

[50]  U. Eriksson,et al.  Phosphoinositide 3-Kinase &ggr;–Deficient Mice Are Protected From Isoproterenol-Induced Heart Failure , 2003 .

[51]  Hugues Bersini,et al.  Integration and cross‐validation of high‐throughput gene expression data: comparing heterogeneous data sets , 2003, FEBS letters.

[52]  J. Singer,et al.  A Framework for Investigating Change over Time , 2003 .

[53]  J. Singer,et al.  Applied Longitudinal Data Analysis , 2003 .

[54]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[55]  M. Lohse,et al.  Inhibition of Na+-H+ Exchange Prevents Hypertrophy, Fibrosis, and Heart Failure in &bgr;1-Adrenergic Receptor Transgenic Mice , 2002, Circulation research.

[56]  E. Goetzl,et al.  The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. , 2001, Journal of molecular and cellular cardiology.

[57]  M. Raynolds,et al.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.

[58]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Lefkowitz,et al.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. , 1998, Circulation.

[60]  B. Groves,et al.  Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. , 1997, The Journal of clinical investigation.

[61]  T. Timek,et al.  Myosin light chain-actin interaction regulates cardiac contractility. , 1995, Circulation research.

[62]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[63]  L. Leinwand,et al.  Ventricular myosin light chain 1 is developmentally regulated and does not change in hypertension. , 1989, Nucleic acids research.

[64]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.